b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31409375</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>24</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1465-542X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>21</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>08</Month>\n                        <Day>13</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Breast cancer research : BCR</Title>\n                <ISOAbbreviation>Breast Cancer Res.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2<sup>+ve</sup> breast cancer metastasis.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>94</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-019-1177-1</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients progress to incurable brain metastases due to acquired resistance and/or limited permeability of inhibitors across the blood-brain barrier. Neratinib, a potent irreversible pan-tyrosine kinase inhibitor, prolongs disease-free survival in the extended adjuvant setting, and several trials evaluating its efficacy alone or combination with other inhibitors in early and advanced HER2-positive breast cancer patients are ongoing. However, its efficacy as a first-line therapy against HER2-positive breast cancer brain metastasis has not been fully explored, in part due to the lack of relevant pre-clinical models that faithfully recapitulate this disease. Here, we describe the development and characterisation of a novel syngeneic model of spontaneous HER2-positive breast cancer brain metastasis (TBCP-1) and its use to evaluate the efficacy and mechanism of action of neratinib.</AbstractText>\n                <AbstractText Label="METHODS">TBCP-1 cells were derived from a spontaneous BALB/C mouse mammary tumour and characterised for hormone receptors and HER2 expression by flow cytometry, immunoblotting and immunohistochemistry. Neratinib was evaluated in vitro and in vivo in the metastatic and neoadjuvant setting. Its mechanism of action was examined by transcriptomic profiling, function inhibition assays and immunoblotting.</AbstractText>\n                <AbstractText Label="RESULTS">TBCP-1 cells naturally express high levels of HER2 but lack expression of hormone receptors. TBCP-1 tumours maintain a HER2-positive phenotype in vivo and give rise to a high incidence of spontaneous and experimental metastases in the brain and other organs. Cell proliferation/viability in vitro is inhibited by neratinib and by other HER2 inhibitors, but not by anti-oestrogens, indicating phenotypic and functional similarities to human HER2-positive breast cancer. Mechanistically, neratinib promotes a non-apoptotic form of cell death termed ferroptosis. Importantly, metastasis assays demonstrate that neratinib potently inhibits tumour growth and metastasis, including to the brain, and prolongs survival, particularly when used as a neoadjuvant therapy.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">The TBCP-1 model recapitulates the spontaneous spread of HER2-positive breast cancer to the brain seen in patients and provides a unique tool to identify novel therapeutics and biomarkers. Neratinib-induced ferroptosis provides new opportunities for therapeutic intervention. Further evaluation of neratinib neoadjuvant therapy is warranted.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Nagpal</LastName>\n                    <ForeName>Aadya</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Redvers</LastName>\n                    <ForeName>Richard P</ForeName>\n                    <Initials>RP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Metastasis Research Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ling</LastName>\n                    <ForeName>Xiawei</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Metastasis Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ayton</LastName>\n                    <ForeName>Scott</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Florey Institute of Neuroscience and Mental Health, Parkville, VIC, 3052, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fuentes</LastName>\n                    <ForeName>Miriam</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tavancheh</LastName>\n                    <ForeName>Elnaz</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Diala</LastName>\n                    <ForeName>Irmina</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Puma Biotechnology, Inc., 10880 Wilshire Blvd, Los Angeles, CA, 90024, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lalani</LastName>\n                    <ForeName>Alshad</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Puma Biotechnology, Inc., 10880 Wilshire Blvd, Los Angeles, CA, 90024, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Loi</LastName>\n                    <ForeName>Sherene</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Translational Breast Cancer Genomics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>David</LastName>\n                    <ForeName>Steven</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Peter MacCallum Cancer Centre, Moorabbin Campus, East Bentleigh, VIC, 3165, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Anderson</LastName>\n                    <ForeName>Robin L</ForeName>\n                    <Initials>RL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Metastasis Research Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3000, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, 3000, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Smith</LastName>\n                    <ForeName>Yvonne</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Royal College of Surgeons, Dublin, D02 YN77, Ireland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Merino</LastName>\n                    <ForeName>Delphine</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Tumour Progression and Heterogeneity Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Molecular Medicine Division, The Walter and ELIZA Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3010, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Denoyer</LastName>\n                    <ForeName>Delphine</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pouliot</LastName>\n                    <ForeName>Normand</ForeName>\n                    <Initials>N</Initials>\n                    <Identifier Source="ORCID">0000-0002-7654-3445</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Matrix Microenvironment &amp; Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, VIC, 3084, Australia. Normand.Pouliot@onjcri.org.au.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>School of Cancer Medicine, La Trobe University, Bundoora, VIC, 3086, Australia. Normand.Pouliot@onjcri.org.au.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, 3000, Australia. Normand.Pouliot@onjcri.org.au.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>13</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Breast Cancer Res</MedlineTA>\n            <NlmUniqueID>100927353</NlmUniqueID>\n            <ISSNLinking>1465-5411</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.1</RegistryNumber>\n                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.1</RegistryNumber>\n                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>JJH94R3PWB</RegistryNumber>\n                <NameOfSubstance UI="C487932">neratinib</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>\n                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>\n                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D064596" MajorTopicYN="N">Isografts</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Brain metastasis</Keyword>\n            <Keyword MajorTopicYN="Y">Ferroptosis</Keyword>\n            <Keyword MajorTopicYN="Y">HER2-positive breast cancer</Keyword>\n            <Keyword MajorTopicYN="Y">Neratinib</Keyword>\n            <Keyword MajorTopicYN="Y">Syngeneic mouse model</Keyword>\n            <Keyword MajorTopicYN="Y">TBCP-1</Keyword>\n            <Keyword MajorTopicYN="Y">Tyrosine kinase inhibitors</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>26</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>26</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31409375</ArticleId>\n            <ArticleId IdType="doi">10.1186/s13058-019-1177-1</ArticleId>\n            <ArticleId IdType="pii">10.1186/s13058-019-1177-1</ArticleId>\n            <ArticleId IdType="pmc">PMC6693253</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Front Aging Neurosci. 2016 Dec 20;8:308</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28066232</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Cell Mol Med. 2017 Apr;21(4):648-657</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27860262</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2017 Feb 28;116(5):620-625</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28152547</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Pharmacol. 2012 Jul;82(1):47-58</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22491935</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2017 Oct 9;8(52):90262-90277</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29163826</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Cancer. 2012 Feb 1;130(3):555-66</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21387294</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bioinformatics. 2012 Aug 15;28(16):2184-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22743226</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2016 Mar 20;34(9):945-52</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26834058</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Biosyst. 2012 Apr;8(5):1553-70</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22446932</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>PLoS One. 2014 Aug 25;9(8):e105961</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25153153</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bioinformatics. 2014 Apr 1;30(7):923-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24227677</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biochem Pharmacol. 2012 Aug 1;84(3):260-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22548830</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA Oncol. 2016 Dec 1;2(12):1557-1564</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27078022</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncol Lett. 2017 Jul;14(1):194-200</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28693153</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Death Dis. 2016 Jul 21;7:e2307</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27441659</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2013 Oct;4(10):1592-605</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24009064</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Chem Biol. 2017 Jan;13(1):91-98</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27842070</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Rep. 2016 Mar 21;6:23383</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26996207</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Exp Ther Med. 2018 Sep;16(3):2183-2192</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30186457</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2018 Apr 15;24(8):1795-1804</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29437794</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">1359541</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Growth Factors. 2014 Apr;32(2):63-73</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24601751</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Anticancer Res. 2014 Nov;34(11):6417-22</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25368241</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2005 Nov;16(11):1772-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16150805</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Breast Cancer Res. 2016 Jun 28;18(1):68</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27349894</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncoimmunology. 2017 Aug 11;6(12):e1362530</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29209569</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am J Cancer Res. 2015 Aug 15;5(9):2531-61</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26609467</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biochem Biophys Res Commun. 2012 Apr 20;420(4):869-74</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22449574</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>BMC Med. 2014 Aug 12;12:132</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25285786</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer Ther. 2017 Feb;16(2):265-272</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28159915</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Front Biosci (Elite Ed). 2016 Jan 01;8:245-63</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26709660</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Exp Metastasis. 2003;20(4):327-34</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12856720</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biochem Biophys Res Commun. 2016 Sep 23;478(3):1338-43</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27565726</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Exp Metastasis. 2013 Jun;30(5):695-710</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23322381</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am J Cancer Res. 2017 Jul 01;7(7):1476-1485</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28744398</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Immunol. 2017 Sep;319:35-42</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28735814</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Dis Model Mech. 2015 Mar;8(3):237-51</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25633981</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Chem Biol. 2008 Mar;15(3):234-45</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18355723</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2013 Oct 1;73(19):5852-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24062312</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21342044</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2017 Dec;18(12):1688-1700</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29146401</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Drug Discov. 2012 Jun 01;11(6):479-97</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22653217</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Oncol. 2014 Dec;45(6):2241-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25230850</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Drug Investig. 2019 Jan;39(1):27-43</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30370488</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Cell. 2003 Mar;3(3):285-96</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12676586</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2002 Feb 1;20(3):719-26</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11821453</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Death Differ. 2016 Mar;23(3):369-79</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26794443</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bioinformatics. 2010 Jan 1;26(1):139-40</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19910308</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2004 Jun 1;64(11):3958-65</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15173008</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3826-3836</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29949159</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Anticancer Drugs. 2007 Jan;18(1):23-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17159499</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2009 Mar 24;100(6):894-900</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19240719</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Signal. 2018 Oct 09;11(551):</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30301790</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Treat Rev. 2018 Jun;67:71-77</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29772459</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2016 Jul 7;375(1):11-22</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27406346</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Methods. 2015 Apr;12(4):357-60</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25751142</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>ACS Cent Sci. 2017 Mar 22;3(3):232-243</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28386601</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Breast. 2017 Feb;31:90-98</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27829201</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Transl Med. 2010 Aug 4;2(43):43ra56</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20686179</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer. 2013 Jul 01;12:69</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23816254</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Breast Cancer (Dove Med Press). 2015 Jun 09;7:147-62</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26089701</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Transl Med. 2017 May 1;15(1):91</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28460632</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CA Cancer J Clin. 2018 Nov;68(6):394-424</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30207593</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Nucl Med. 2011 Jan;52(1):115-22</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21149487</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Pharmacol Exp Ther. 2012 Nov;343(2):342-50</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22888144</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ther Adv Med Oncol. 2016 Sep;8(5):339-50</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27583026</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Mol Life Sci. 2016 Jun;73(11-12):2195-209</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27048822</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2017 Aug 10;8(42):72260-72271</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29069785</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2005 Oct 20;353(16):1673-84</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16236738</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2012 May 25;149(5):1060-72</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22632970</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Dis Model Mech. 2018 Jul 6;11(7):</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29784888</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Front Pharmacol. 2018 Jan 12;8:992</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29375387</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'